Edgewise Therapeutics, Inc. EWTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $33.21M-33.5% | $61.15M+46.8% | $46M+2.7% | $43.4M-0.2% | $49.92M+65.0% | ||
| $509.79M+15.0% | $543.39M+14.3% | $573.9M+14.9% | $603.26M+16.1% | $443.18M-18.1% | ||
| $7.4M-17.7% | $7.83M-17.6% | $8.13M-18.4% | $8.6M-13.2% | $8.99M-11.7% | ||
| $518.52M+14.1% | $552.6M+13.5% | $583.47M+14.1% | $613.33M+15.4% | $454.39M-18.0% | ||
| $27.78M+3.6% | $29.27M+28.7% | $28.85M+36.1% | $28.34M+35.8% | $26.82M+50.3% | ||
| $22.54M+6.8% | $27.37M+14.7% | $21.65M+14.2% | $20.9M+21.7% | $21.12M+44.6% | ||
| $25.32M+2.6% | $30.35M+9.9% | $24.82M+10.8% | $24.26M+14.6% | $24.67M+30.8% | ||
| $10K+11.1% | $10K+11.1% | $10K+11.1% | $10K+11.1% | $9K0.0% | ||
| -$595.38M-42.0% | -$546.37M-44.3% | -$496.16M-46.4% | -$455.49M-49.4% | -$419.37M-53.5% | ||
| $493.2M+14.8% | $522.26M+13.7% | $558.65M+14.3% | $589.07M+15.4% | $429.72M-19.7% | ||
| $518.52M+14.1% | $552.6M+13.5% | $583.47M+14.1% | $613.33M+15.4% | $454.39M-18.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Edgewise Therapeutics, Inc.'s total assets?
- Edgewise Therapeutics, Inc. (EWTX) holds $518.5M in total assets, up 14.1% year over year.
- How much debt does Edgewise Therapeutics, Inc. have?
- Edgewise Therapeutics, Inc. carries $3.8M in total debt against $493.2M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Edgewise Therapeutics, Inc. have?
- Edgewise Therapeutics, Inc. holds $33.2M in cash and equivalents.
- Can Edgewise Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.61 — current assets exceed current liabilities.
- Where does Edgewise Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.